Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice.
Pandemic H1N1 influenza vaccine antigens are currently being manufactured. The MF59 adjuvant has an established safety profile in humans and a proven ability to increase responses to some influenza vaccines in humans. To inform initial decisions on the use of these vaccine components to protect human populations, we have immunized mice with MF59-adjuvanted or non-adjuvanted pandemic influenza vaccine. Immunizing unprimed mice with a single dose of MF59-adjuvanted vaccine elicits functional antibody titers equivalent to those associated with protection of humans from seasonal influenza. Without adjuvant, two doses are required for a robust antibody response. Unadjuvanted vaccines with 0.5 and 1 microgram of antigen elicit equivalent titers. These data support including MF59 in pandemic flu vaccines to rapidly protect young adults and children, who may have little or no previous exposure to influenza infection or immunization.
Novartis Vaccines and Diagnostics, Cambridge, MA, USA; Novartis Vaccines & Diagnostics; Novartis Vaccines; University of Siena; Novartis and Division of Immunoregulation, National Institute for Medical Research, The Ridgeway, London NW7 1AA.
Philip R
PR
Dormitzer
Rino
R
Rappuoli
Daniele
D
Casini
Derek
D
O'Hagan
Celene
C
Runham
Emanuele
E
Montomoli
Barbara
B
Baudner
John J
JJ
Donnelly Iii
Giulia
G
Lapini
Andreas
A
Wack